MERCAPTOPURINE (6-MP, 6-MERCAPTOPURINE)  (mer-kap-toe-pyoor'een)  Purinethol Classifications: antineoplastic; antimetabolite, purine antagonist; immunosuppressant; Therapeutic: antineoplastic; immunosuppressant Pregnancy Category: D
|
Availability
50 mg tablets
Action
Antimetabolite and purine antagonist. Inhibits purine metabolism. Blocks conversion of inosinic acid to adenine and xanthine
ribotides within sensitive tumor cells. Also inhibits adenine-containing coenzymes, suggesting an influence over multiple
cellular reactions.
Therapeutic Effect
Delayed immunosuppressive properties and carcinogenic potential.
Uses
Primarily for acute lymphocytic and myelogenous leukemia. Response in adults is less than in children, but mercaptopurine
is initial drug of choice. In chronic granulocytic leukemia, produces temporary remission.
Unlabeled Uses
Prevention of transplant graft rejection; SLE; rheumatoid arthritis; Crohn's disease.
Contraindications
Prior resistance to mercaptopurine; first trimester of pregnancy (category D); lactation; infections.
Cautious Use
Impaired kidney or liver function; concomitant use with allopurinol.
Route & Dosage
Leukemias Adult/Child: PO Loading Dose 2.5 mg/kg/d, may increase up to 5 mg/kg/d after 4 wk if needed PO Maintenance Dose 1.252.5 mg/kg/d
|
Administration
Oral
- Give total daily dose at one time.
- Reduce dose of mercaptopurine usually by 1/31/4 when given concurrently with allopurinol.
- Store tablets in light- and air-resistant container.
Adverse Effects (≥1%)
GI: Stomatitis, esophagitis, anorexia, nausea, vomiting,
diarrhea, intestinal ulcerations, impaired liver function,
hepatic necrosis. Hematologic: Leukopenia, anemia, eosinophilia,
pancytopenia,
thrombocytopenia, abnormal bleeding,
bone marrow hypoplasia.
Urogenital: Hyperuricemia, oliguria,
renal impairment.
Skin: Rash.
Body as a Whole: Drug fever.
Interactions
Drug: Allopurinol may inhibit
metabolism and thus increase
toxicity of mercaptopurine; may potentiate or antagonize anticoagulant effects
of
warfarin.
Pharmacokinetics
Absorption: Approximately 50% absorbed from GI tract.
Peak: 2 h.
Distribution: Distributes into total body water.
Metabolism: Rapidly by xanthine oxidase in liver.
Elimination: 11% in urine within 6 h.
Half-Life: 2050 min.
Nursing Implications
Assessment & Drug Effects
- Lab tests: Monitor CBC with differential, platelet count, Hgb, Hct, and liver functions closely.
- Monitor for S&S of liver damage. Hepatic toxicity occurs most often when dose exceeds 2.5 mg/kg/d. Jaundice signals onset
of hepatic toxicity and may necessitate terminating use.
- Withhold drug and notify physician at the first sign of an abnormally large or rapid fall in platelet and leukocyte counts.
- Record baseline data related to I&O ratio and pattern and body weight.
- Check vital signs daily. Report febrile states promptly.
- Protect patient from exposure to trauma, infections, or other stresses (restrict visitors and personnel who have colds)
during periods of leukopenia.
- Report nausea, vomiting, or diarrhea. These may signal excessive dosage, especially in adults.
- Watch for signs of abnormal bleeding (ecchymoses, petechiae, melena, bleeding gums) if thrombocytopenia develops; report
immediately.
Patient & Family Education
- Report any signs of bleeding (e.g., hematuria, bruising, bleeding gums).
- Report signs of hepatic toxicity (see Appendix F).
- Increase hydration (1012 glasses of fluid daily) to reduce risk of hyperuricemia. Consult physician about desirable
volume.
- Notify physician of onset of chills, nausea, vomiting, flank or joint pain, swelling of legs or feet, or symptoms of anemia.